

Headlines Advinus Therapeutics & Veeda CR forge strategic alliance

Date November 7 2006

Media Resource <http://news.moneycontrol.com/>

Description

In a unique initiative to combine synergies from complementary capabilities, Advinus Therapeutics and Veeda CR has forged a strategic alliance. The companies intend to leverage each other's capabilities to create an integrated Drug Discovery through Phase II platform.

The alliance will offer packages involving preclinical and early clinical development, animal and human safety pharmacology, preclinical toxicology and pharmacology, clinical pharmacology as also microdosing capabilities to pick drug candidates on the basis of human PK data. The alliance will seek to leverage Veeda's biomarkers capabilities for preclinical and clinical applications.

The alliance will set a new precedence in the emerging Drug discovery industry in the country and will attract companies looking for preclinical and clinical services in the European and American geographies. Existing clients of both companies will also be able to leverage the seamless preclinical and early clinical development capabilities of the alliance.

Dr. Rashmi Barbhैया, CEO and MD, Advinus said, "Veeda CR is a partner of choice with its technical expertise in handling complex early clinical development trials, compliance with regulatory standards and focus on ethics. Our alliance offers seamless access to our combined capabilities in preclinical and early clinical development of drug candidates to our clients. This partnership represents an important milestone in our strategy to offer integrated R&D services to our partners."

Dr. Apurva Shah, MD, Veeda CR said, "Our association with Advinus provides access to their preclinical and pharmaceutical development capabilities and a world-class development team. Our combined capabilities will offer unique opportunities for developing INDs and for early clinical development to our clients in a seamless manner."